711TiP A phase I/II, first-in-human, open-label, dose-escalation study of TAK-186, an EGFR × CD3ε COBRA T cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors.
Saved in:
| Title: | 711TiP A phase I/II, first-in-human, open-label, dose-escalation study of TAK-186, an EGFR × CD3ε COBRA T cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors. |
|---|---|
| Authors: | Weickhardt, A.J.1 (AUTHOR), Frentzas, S.2 (AUTHOR), Lemech, C.3 (AUTHOR), Srimani, J.4 (AUTHOR), Yin, J.5 (AUTHOR), Trepicchio, W.L.6 (AUTHOR), Gorgun, C.7 (AUTHOR), Kichenadasse, G.8 (AUTHOR) |
| Source: | Annals of Oncology. 2023 Supplement 2, Vol. 34, pS492-S492. 1p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 173098762 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: 711TiP A phase I/II, first-in-human, open-label, dose-escalation study of TAK-186, an EGFR × CD3ε COBRA T cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Weickhardt%2C+A%2EJ%2E%22">Weickhardt, A.J.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Frentzas%2C+S%2E%22">Frentzas, S.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lemech%2C+C%2E%22">Lemech, C.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Srimani%2C+J%2E%22">Srimani, J.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Yin%2C+J%2E%22">Yin, J.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Trepicchio%2C+W%2EL%2E%22">Trepicchio, W.L.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gorgun%2C+C%2E%22">Gorgun, C.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kichenadasse%2C+G%2E%22">Kichenadasse, G.</searchLink><relatesTo>8</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2023 Supplement 2, Vol. 34, pS492-S492. 1p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=173098762 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2023.09.1897 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 1 StartPage: S492 Titles: – TitleFull: 711TiP A phase I/II, first-in-human, open-label, dose-escalation study of TAK-186, an EGFR × CD3ε COBRA T cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Weickhardt, A.J. – PersonEntity: Name: NameFull: Frentzas, S. – PersonEntity: Name: NameFull: Lemech, C. – PersonEntity: Name: NameFull: Srimani, J. – PersonEntity: Name: NameFull: Yin, J. – PersonEntity: Name: NameFull: Trepicchio, W.L. – PersonEntity: Name: NameFull: Gorgun, C. – PersonEntity: Name: NameFull: Kichenadasse, G. IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 10 Text: 2023 Supplement 2 Type: published Y: 2023 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 34 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |
